Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
1. VRTX expected earnings at $4.29 per share, down from $4.76 last year. 2. Projected revenue for Q1 is $2.86 billion, an increase from $2.69 billion. 3. Company delays VX-264 clinical trial for type 1 diabetes developments. 4. Analysts maintain positive ratings, with targets up to $567. 5. Stock rose by 0.5% closing at $501.15 before earnings release.